Skye Bioscience Inc. (09R0)
XMUN 
NASDAQ (NMS) Primary XMUN Summary
09R0 Chart
Arecor partners with Skye Bioscience to improve formulation of obesity drug
Arecor Therapeutics PLC (AIM:AREC) has entered a development partnership with Skye Bioscience Inc (NASDAQ:SKYE), a US-based biotechnology group, to create a more concentrated formulation of an experimental obesity treatment, as drugmakers vie for a share of the fast-growing weight-loss market. The Cambridge-based company will use its proprietary Arestat technology to reformulate nimacimab, a monoclonal antibody developed by Skye that targets the CB1 receptor.
Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript
Skye Bioscience, Inc. (NASDAQ:SKYE ) Q1 2025 Earnings Conference Call May 9, 2025 4:30 PM ET Company Participants Bernie Hertel - Head of Investor Relations Punit Dhillon - President & Chief Executive Officer Chris Twitty - Chief Scientific Officer Kaitlyn Arsenault - Chief Financial Officer Puneet Arora - Chief Medical Officer Tu Diep - Chief Operating Officer Conference Call Participants Jay Olson - Oppenheimer Albert Lowe - Craig-Hallum Ted Tenthoff - Piper Sandler Kristen Kluska - Cantor Fitzgerald Andy Hsieh - William Blair Jon Wolleben - Citizens JMP Bernie Hertel Hello, and thank you all for participating in today's call. Joining me today is Punit Dhillon, Skye's President and CEO; Chris Twitty, CSO, and Kaitlyn Arsenault, Skye's CFO.
A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value
Weight loss drug stocks like Novo Nordisk have dropped significantly lately. This presents potential value opportunities in a market projected to grow to $105 billion by 2035. Skye Bioscience's nimacimab, in Phase 2a trials, shows promise with significant weight loss results in mouse models, making it a speculative but potentially rewarding investment. 26-week results for the Phase 2a are expected in late Q3 or early Q4, so positive catalysts are on the horizon.
Skye Bioscience Inc. Dividends
Skye Bioscience Inc. Earnings
| 8 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 8 May 2025 Date | | - Cons. EPS | - EPS |
| 19 Mar 2025 Date | | - Cons. EPS | - EPS |
| 31 Mar 2024 Date | | - Cons. EPS | - EPS |
| 22 Mar 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 8 May 2025 Date | | - Cons. EPS | - EPS |
| 19 Mar 2025 Date | | - Cons. EPS | - EPS |
| 31 Mar 2024 Date | | - Cons. EPS | - EPS |
| 22 Mar 2024 Date | | - Cons. EPS | - EPS |
Skye Bioscience Inc. (09R0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Skye Bioscience Inc. ever had a stock split?
Skye Bioscience Inc. Profile
| Biotechnology Industry | Healthcare Sector | Punit S. Dhillon CEO | XMUN Exchange | US83086J2006 ISIN |
| US Country | 16 Employees | - Last Dividend | 8 Sep 2023 Last Split | 2 Apr 2015 IPO Date |
Overview
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company engaged in the discovery, development, and potential commercialization of therapeutic drugs aimed at modulating the endocannabinoid system. With a strategic focus on generating transformative treatments, Skye Bioscience endeavors to address unmet medical needs across various domains. Originally known as Emerald Bioscience, Inc., the company underwent a name change in January 2021 to better align with its expanded vision and strategic goals. Skye Bioscience has established its headquarters in San Diego, California, leveraging the region's rich biotechnological ecosystem to advance its research and development efforts.
Products and Services
- Nimacimab
As Skye Bioscience's lead clinical program, nimacimab represents a pioneering approach in targeting the endocannabinoid system. Specifically designed as a peripherally-restricted negative allosteric modulating antibody, nimacimab focuses on the human cannabinoid receptor 1 (CB1). The therapeutic intent of targeting CB1 receptors, primarily involved in metabolic processes, positions nimacimab as a potential treatment for metabolic disorders, including obesity. Currently undergoing Phase II clinical trials, nimacimab is administered as a subcutaneous injection, reflecting Skye Bioscience's commitment to innovative and patient-friendly therapeutic solutions.
- SBI-100 Ophthalmic Emulsion
Expanding its portfolio into ophthalmology, Skye Bioscience is developing the SBI-100 Ophthalmic Emulsion, a CB1 agonist aimed at treating glaucoma and ocular hypertension. This novel formulation is in Phase II clinical trials, underscoring the company's dedication to leveraging the therapeutic potential of the endocannabinoid system across a spectrum of diseases. The SBI-100 Ophthalmic Emulsion represents a significant stride towards offering new treatment options for patients with eye conditions that are often challenging to manage effectively.
- Collaborative Development Efforts
In its pursuit of broadening the therapeutic applications of its research, Skye Bioscience has entered into a licensing agreement with Tautomer Bioscience, (Pty) Limited. This partnership focuses on the development and commercialization of SBI-100. Additionally, a collaborative research agreement with VivaCell Biotechnology Espana, S.L.U is in place for the research and development of SBI-200, as well as the provision of preclinical development services for novel derivatives. These collaborations highlight Skye Bioscience's strategy of leveraging partnerships to accelerate the development of innovative therapies.
Contact Information
